Cytogenetic aspects of the Canadian early and mid-trimester amniotic fluid trial (CEMAT)
Copyright 1999 John Wiley & Sons, Ltd..
Cytogenetic results from a large multicentre randomized controlled study of 2108 amniotic fluids obtained at 11+0-12+6 weeks (EA) and 1999 fluids at 15+0-16+6 weeks (MA) were compared. There was no statistically significant difference in the rate of chromosome abnormalities (EA =1.9 per cent; MA=1.7 per cent) or level III mosaicism (EA=0.2 per cent; MA= 0.2 per cent) between the groups. Level I and Level II mosaicism occurred more frequently in MA. Maternal cell contamination was not significantly different between the groups, but maternal cells only were analysed from one bloody EA fluid. The number of repeat amniocenteses because of cytogenetic problems was 2.2 per cent in the EA group compared with only 0.3 per cent in the MA group. On average, culture of EA fluids required one day more than MA fluids. Although both culture success (97.7 per cent) and accuracy (99.8 per cent) were high for patients randomized to the EA group, routine amniocentesis prior to 13 weeks' gestation is not recommended for clinical reasons including an increased risk of fetal loss and talipes equinovarus.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Prenatal diagnosis - 19(1999), 7 vom: 30. Juli, Seite 620-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Winsor, E J [VerfasserIn] |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 19.08.1999 Date Revised 05.09.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM103513019 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM103513019 | ||
| 003 | DE-627 | ||
| 005 | 20231222130533.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0345.xml |
| 035 | |a (DE-627)NLM103513019 | ||
| 035 | |a (NLM)10419609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Winsor, E J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytogenetic aspects of the Canadian early and mid-trimester amniotic fluid trial (CEMAT) |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.1999 | ||
| 500 | |a Date Revised 05.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 1999 John Wiley & Sons, Ltd. | ||
| 520 | |a Cytogenetic results from a large multicentre randomized controlled study of 2108 amniotic fluids obtained at 11+0-12+6 weeks (EA) and 1999 fluids at 15+0-16+6 weeks (MA) were compared. There was no statistically significant difference in the rate of chromosome abnormalities (EA =1.9 per cent; MA=1.7 per cent) or level III mosaicism (EA=0.2 per cent; MA= 0.2 per cent) between the groups. Level I and Level II mosaicism occurred more frequently in MA. Maternal cell contamination was not significantly different between the groups, but maternal cells only were analysed from one bloody EA fluid. The number of repeat amniocenteses because of cytogenetic problems was 2.2 per cent in the EA group compared with only 0.3 per cent in the MA group. On average, culture of EA fluids required one day more than MA fluids. Although both culture success (97.7 per cent) and accuracy (99.8 per cent) were high for patients randomized to the EA group, routine amniocentesis prior to 13 weeks' gestation is not recommended for clinical reasons including an increased risk of fetal loss and talipes equinovarus | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Tomkins, D J |e verfasserin |4 aut | |
| 700 | 1 | |a Kalousek, D |e verfasserin |4 aut | |
| 700 | 1 | |a Farrell, S |e verfasserin |4 aut | |
| 700 | 1 | |a Wyatt, P |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Y S |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, R |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, H |e verfasserin |4 aut | |
| 700 | 1 | |a Dallaire, L |e verfasserin |4 aut | |
| 700 | 1 | |a Eydoux, P |e verfasserin |4 aut | |
| 700 | 1 | |a Welch, J P |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, A |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, J C |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, J |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, J |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, R D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Prenatal diagnosis |d 1980 |g 19(1999), 7 vom: 30. Juli, Seite 620-7 |w (DE-627)NLM012597317 |x 1097-0223 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:1999 |g number:7 |g day:30 |g month:07 |g pages:620-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 1999 |e 7 |b 30 |c 07 |h 620-7 | ||